Alison Bourke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2397178/publications.pdf

Version: 2024-02-01

		1478505	1372567
10	390	6	10
papers	citations	h-index	g-index
10	10	10	662
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiology and Drug Safety, 2012, 21, 1-10.	1.9	283
2	Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy. JMIR Public Health and Surveillance, 2015, 1, e22.	2.6	26
3	Considerations when evaluating realâ€world data quality in the context of fitness for purpose. Pharmacoepidemiology and Drug Safety, 2020, 29, 1316-1318.	1.9	21
4	Evidence generation from healthcare databases: recommendations for managing change. Pharmacoepidemiology and Drug Safety, 2016, 25, 749-754.	1.9	13
5	Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety, 2020, 29, 1540-1549.	1.9	13
6	Balancing the Interests of Patient Data Protection and Medication Safety Monitoring in a Public-Private Partnership. JMIR Medical Informatics, 2015, 3, e18.	2.6	12
7	Comparison of electronic selfâ€reported prescription medication use during pregnancy with the national prescription register in Denmark. Pharmacoepidemiology and Drug Safety, 2020, 29, 328-336.	1.9	8
8	Supervised Clustering for Subgroup Discovery: An Application to COVID-19 Symptomatology. Communications in Computer and Information Science, 2021, , 408-422.	0.5	7
9	An International Study of the Ability and Cost-Effectiveness of Advertising Methods to Facilitate Study Participant Self-Enrolment Into a Pilot Pharmacovigilance Study During Early Pregnancy. JMIR Public Health and Surveillance, 2016, 2, e13.	2.6	5
10	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) ―EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 2019, 28, 1640-1641.	1.9	2